Don Freeman

    • Don Freeman's details
      • Country: United States
      • Region: Boston
      • Studies: Angel Investor
      • University: Boston Harbor Angels
    • Don Freeman's presentations

    Donald C. Freeman, Jr., PhD, a member of Boston Harbor Angels, was president/CEO of HydroCision, Inc., a fluidjet-based medical device company, from 1996 to 2002, when he retired, remaining on the board. From 1996 until 2000, he was also Chairman, CEO and a Director of RadioMed Corporation, a developer of medical devices incorporating radioisotopes for inhibition of cellular proliferation. RadioMed was acquired by IBA in 2000. Prior to 1996, Dr. Freeman was a Principal of Grayson & Associates, an investment banking firm specializing in the healthcare field. Previously, he was president/CEO of Intra-Sonix, Inc. and Xenotech Laboratories, both medical device companies. Still earlier, he was President of Davol, Inc., which was acquired by C. R. Bard, after which he served as a Group Vice President of Bard. Before Davol, he was President of Friesen International, a hospital design firm owned by American Medical International. He was Director, New Business Development for Union Carbide Corp., where he was also General Manager of its clinical diagnostics, radiopharmaceuticals and imaging buesinesses. Dr. Freeman’s early career was as a scientist at Union Carbide. He holds an ScB from Brown and a PhD in chemistry from the University of Maryland, and did post-doctoral research in physics at Duke. He is inventor or co-inventor on some 19 US patents. He attended the Harvard Business School Advanced Management Program and has been a Director of numerous companies, public and private, in the healthcare field. He is currently on the board of PhotoBioChem (Leiden, NL), SemiNex (Mass), Medical Record Bank(Mass) Electrolyzer Corporation (Mass) and Pluromed Corporation (Mass) as well as HydroCision. He holds investments in those companioes, in addition to 6 other early-stage ventures.